Assuntos
Pólipos Nasais , Rinossinusite , Índice de Gravidade de Doença , Tenascina , Células Th2 , Feminino , Humanos , Masculino , Doença Crônica , Edema , Pólipos Nasais/imunologia , Pólipos Nasais/metabolismo , Pólipos Nasais/complicações , Rinossinusite/complicações , Rinossinusite/imunologia , Rinossinusite/metabolismo , Tenascina/metabolismo , Células Th2/imunologia , Células Th2/metabolismoRESUMO
Background: The incidence of carbapenem-resistant organism (CRO) infections is increasing in children. However, pediatric-specific treatment strategies present unique challenges. Ceftazidime/avibactam is a ß-lactam/ß-lactamase inhibitor combination, showing adequate efficiency against CRO isolates. However, clinical data on the efficacy of ceftazidime/avibactam in children are still lacking. Methods: This was a retrospective study of children (aged <18 years) infected with confirmed or suspected carbapenem-resistant pathogens and treated with ceftazidime-avibactam at the First Affiliated Hospital of Zhengzhou University between 2020 and 2022. Results: We identified 38 children aged 14 (5.0-16.3) years; 20 (52.6%) had hematologic malignancies. 25 children with confirmed CRO infections were administered ceftazidime-avibactam as targeted therapy. The median treatment was 10 (6.0-16.5) days. Among them, 24 had infections caused by carbapenem-resistant Enterobacterales (CRE) (18 carbapenem-resistant Klebsiella pneumoniae and six carbapenem-resistant Escherichia coli species) and one with carbapenem-resistant Pseudomonas aeruginosa strains. The source of infection was the bloodstream in 60.0% of the cases (15/25). The clinical response rate was 84.0% (21/25), and 30-day mortality rate was 20% (5/25). 13 children were administered ceftazidime-avibactam as empiric therapy for suspected infections. The median treatment was 8 (6.0-13.0) days. No deaths occurred and clinical response was achieved in 12 of the 13 patients (92.3%) who empirically treated with ceftazidime-avibactam. Conclusion: Ceftazidime-avibactam is important for improving survival, and clinical response in children with infections caused by CRO.
RESUMO
Obesity is characterized by chronic low-grade inflammation and is strongly associated with multiple immunological diseases, including cancer and inflammatory diseases. Recent animal studies revealed that obesity-induced immunological changes worsen immune-driven diseases and cause resistance to immunotherapy. Here, we discuss the role of obesity in the immunopathology and treatment responses of cancers, respiratory and allergic diseases, and IL-17-mediated inflammatory diseases. We summarize the unique features of the inflammatory state of these diseases, which are orchestrated by obesity. In particular, obesity alters the immune landscape in cancers with a reprogrammed metabolic profile of tumor-infiltrating immune cells. Obesity exacerbates airway inflammation by dysregulating multiple immune-cell subsets. Obesity also dysregulates Th17, IL-17-producing mucosal-associated invariant T (MAIT), and γδ T cells, which contribute to IL-17-mediated inflammatory response in multiple sclerosis, inflammatory bowel disease, psoriasis, atopic dermatitis, and rheumatoid arthritis. By identifying the effects of obesity on immunological diseases, new strategies could be devised to target immune dysregulation caused by obesity.
Assuntos
Artrite Reumatoide , Neoplasias , Animais , Interleucina-17/metabolismo , Inflamação/etiologia , Artrite Reumatoide/complicações , Obesidade/complicaçõesRESUMO
Background: This study aimed to identify risk factors for mortality and outcomes in hematological malignancy (HM) patients with bloodstream infection (BSI) caused by carbapenem-resistant Klebsiella pneumoniae (CRKP). Methods: A retrospective study was conducted at a tertiary teaching hospital in Henan Province, China, between January 2018 and December 2021. All BSIs caused by CRKP in hospitalized HM patients were identified. Data on patient demographics, disease, laboratory tests, treatment regimens, outcomes of infection, and the antimicrobial susceptibility of each isolate were collected from medical records. Results: A total of 129 patients with CRKP BSI were included in the study, and the 28-day mortality rate was 80.6% (104/129). In Cox analysis an absolute neutrophil count < 500 at discharge (hazard ratio [HR] 6.386, 95% confidence interval [CI] 3.074-13.266, p < 0.001), intensive care unit admission (HR 1.834, 95% CI 1.065-3.157, p = 0.029), and higher Pitt bacteremia score (HR 1.185, 95% CI 1.118-1.255, p < 0.001) were independent risk factors associated with 28-day mortality. Survival curve analysis indicated that compared with ceftazidime-avibactam-based therapy, both polymyxin b (HR 8.175, 95% CI 1.099-60.804, p = 0.040) and tigecycline (HR 14.527, 95% CI 2.000-105.541, p =0.008) were associated with a higher risk of mortality. Conclusion: In HM patients CRKP BSI resulted in high mortality. Intensive care unit admission, higher Pitt bacteremia score, and absolute neutrophil count < 500 at discharge were independently associated with higher mortality. Early initiation of new agents such as ceftazidime-avibactam may improve outcomes.
RESUMO
BACKGROUND: The reporting quality of clinical practice guidelines (CPGs) for gliomas has not yet been thoroughly assessed. The International Reporting Items for Practice Guidelines in Healthcare (RIGHT) statement developed in 2016 provides a reporting framework to improve the quality of CPGs. We aimed to estimate the reporting quality of glioma guidelines using the RIGHT checklist and investigate how the reporting quality differs by selected characteristics. METHODS: We systematically searched electronic databases, guideline databases, and medical society websites to retrieve CPGs on glioma published between 2018 and 2020. We calculated the compliance of the CPGs to individual items, domains and the RIGHT checklist overall. We performed stratified analyses by publication year, country of development, reporting of funding, and impact factor (IF) of the journal. RESULTS: Our search revealed 20 eligible guidelines. Mean overall adherence to the RIGHT statement was 54.6%. Eight CPGs reported more than 60% of the items, and five reported less than 50%. All guidelines adhered to the items 1a, 3, 7a, 13a, while no guidelines reported the items 17 or 18b (see http://www.right-statement.org/right-statement/checklist for a description of the items). Two of the seven domains, "Basic information" and "Background", had mean reporting rates above 60%. The "Review and quality assurance" domain had the lowest mean reporting rate, 12.5%. The reporting quality of guidelines published in 2020, guidelines developed in the United States, and guidelines that reported funding tended to be above average. CONCLUSIONS: The reporting quality of CPGs on gliomas is low and needs improvement. Particular attention should be paid on reporting the external review and quality assurance process. The use of the RIGHT criteria should be encouraged to guide the development, reporting and evaluation of CPGs.
RESUMO
With the growing use of immune checkpoint inhibitors (ICIs), case reports of rare yet life-threatening pituitary-adrenal dysfunctions, particularly for hypopituitarism, are increasingly being published. In this analysis, we focus on these events by including the most recent publications and reports from early phase I/II and phase III clinical trials and comparing the incidence and risks across different ICI regimens. PubMed, Embase, and the Cochrane Library were systematically searched from inception to April 2019 for clinical trials that reported on pituitary-adrenal dysfunction. The rates of events, odds ratios (ORs), and 95% confidence intervals (CIs) were obtained using random effects meta-analysis. The analyses included data from 160 trials involving 40 432 participants. The rate was 2.43% (95% CI, 1.73%-3.22%) for all-grade adrenal insufficiency and 3.25% (95% CI, 2.15%-4.51%) for hypophysitis. Compared with the placebo or other therapeutic regimens, ICI agents were associated with a higher incidence of serious-grade adrenal insufficiency (OR 3.19, 95% CI, 1.84 to 5.54) and hypophysitis (OR 4.77, 95% CI, 2.60 to 8.78). Among 71 serious-grade hypopituitarism instances in 12 336 patients, there was a significant association between ICIs and hypopituitarism (OR 3.62, 95% CI, 1.86 to 7.03). Substantial heterogeneity was noted across the studies for the rates of these events, which in part was attributable to the different types of ICIs and varied phases of the clinical trials. Although the rates of these events were low, the risk was increased following ICI-based treatment, particularly for CTLA-4 inhibitors, which were associated with a higher incidence of pituitary-adrenal dysfunction than PD-1/PD-L1 inhibitors.
Assuntos
Antineoplásicos Imunológicos/efeitos adversos , Sistema Hipófise-Suprarrenal/efeitos dos fármacos , Insuficiência Adrenal/diagnóstico , Insuficiência Adrenal/etiologia , Antineoplásicos Imunológicos/uso terapêutico , Biomarcadores Tumorais , Antígeno CTLA-4/antagonistas & inibidores , Ensaios Clínicos como Assunto , Humanos , Hipopituitarismo/diagnóstico , Hipopituitarismo/etiologia , Neoplasias/complicações , Neoplasias/tratamento farmacológico , Neoplasias/etiologia , Razão de Chances , Testes de Função Adreno-Hipofisária , Receptor de Morte Celular Programada 1/antagonistas & inibidores , Índice de Gravidade de DoençaRESUMO
Background: Immune checkpoint inhibitors (ICIs) are now an important option for more than 14 different cancers. Recent series case reports have described that ICIs are associated with new-onset diabetes in patients, yet the definitive risk is not available. We thus performed a meta-analysis of randomized controlled trials (RCTs) to assess the incidence and risk of developing new-onset diabetes following the use of ICIs. Methods: The PubMed, EMBASE, Cochrane Library databases, and ClinicalTrials.gov for RCTs were searched. Statistical analyses were performed using STATA 15 and R language. Fifty-two RCTs were included, and 12 did not report any events of ICI-associated diabetes. Results: A meta-analysis of 40 trials was performed, which reported at least one diabetes-related event among 24,596 patients. Although specific diabetes-related events were rare, compared with the placebo or other therapeutic strategies, the rates of serious hyperglycemia (OR 2.41, 95% CI 1.52 to 3.82), diabetes (3.54, 1.32 to 9.51), all-grade T1D (6.60, 2.51 to 17.30), and serious-grade T1D (6.50, 2.32 to 18.17) were increased with ICI drugs. Subgroup analysis according to the type of control, type of ICIs, and the combination mode suggested that ICIs plus conventional treatments significantly decreased the risks of diabetes and serious-grade hyperglycemia. There was little heterogeneity across the studies in all results except hyperglycemic events, which in part was attributable to data from everolimus-based control group. Conclusions: New-onset diabetes is uncommon with ICIs but the risk is increased compared with placebo or another therapeutic strategy. However, more studies are warranted to substantiate these findings across ICIs.